Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 139Breast Neoplasms 31Prostatic Neoplasms 29Insulin Resistance 28Obesity 19Pancreatic Neoplasms 13Neoplasms 12Infertility 12Endometrial Neoplasms 12Carcinoma, Non-Small-Cell Lung 12Colorectal Neoplasms 11Anovulation 9Lung Neoplasms 8Metabolic Syndrome 7Melanoma 7Hyperandrogenism 7Glioblastoma 7Diabetes Mellitus 7Squamous Cell Carcinoma of Head and Neck 6Neoplasm Metastasis 6Rectal Neoplasms 5Adenocarcinoma 5Weight Loss 4Urinary Bladder Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Head and Neck Neoplasms 4Carcinoma, Ovarian Epithelial 4Adenocarcinoma of Lung 4Uterine Cervical Neoplasms 3Recurrence 3

Interventions

Metformin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Progression-Free Survival × Metformin × Clear all
NCT06826092 2025-02-13

Metformin for the Treatment of mCRC Patients Undergoing FOLFIRI Plus Target Therapy

Kaohsiung Medical University Chung-Ho Memorial Hospital

Phase 2 Recruiting
110 enrolled

Progression-Free Survival

Data powered by HemOnc (CC BY 4.0) Colophon âš¡